aprocitentan

a macitentan metabolite

Also Known As:

ACT-132577; N-(5-(4-Bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)sulfuric diamide; sulfamide, N-(5-(4-bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)-

Networked: 25 relevant articles (2 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - aprocitentan: 25
Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - aprocitentan: 25
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - aprocitentan: 25

Experts

1.	Dingemanse, Jasper: 7 articles (01/2021 - 01/2019)
2.	Sidharta, Patricia N: 7 articles (01/2021 - 01/2019)
3.	Clozel, Martine: 2 articles (07/2022 - 01/2019)
4.	Bellet, Marc: 2 articles (01/2022 - 01/2020)
5.	Danaietash, Parisa: 2 articles (01/2022 - 01/2020)
6.	Verweij, Pierre: 2 articles (01/2022 - 01/2020)
7.	Burnier, Michel: 2 articles (01/2021 - 01/2018)
8.	Flamion, Bruno: 2 articles (01/2021 - 01/2020)
9.	Iglarz, Marc: 2 articles (01/2021 - 01/2019)
10.	Ménard, Joël: 2 articles (01/2020 - 01/2019)

Related Diseases

1.	Hypertension (High Blood Pressure) 12/01/2021 - "In conclusion, aprocitentan ameliorates the effects of ET-1 and could potentially reduce BP and provide broader cardiovascular protection in patients with resistant hypertension. " 12/01/2021 - "Aprocitentan in patients with resistant hypertension is currently under investigation in the PRECISION phase III trial (ClinicalTrials identifier: NCT03541174). " 07/01/2023 - "Aprocitentan significantly reduced systolic and diastolic blood pressure with both doses of 10mg and 25mg in patients with hypertension. " 07/01/2023 - "The main goal was to determine the effect of aprocitentan on blood pressure among patients with hypertension. " 01/01/2023 - "Aprocitentan: A new development of resistant hypertension."
2.	Breast Neoplasms (Breast Cancer) 11/01/2020 - "The drug-drug interaction potential of aprocitentan on the breast cancer resistance protein (BCRP) transporter substrate rosuvastatin was investigated in this single-center, open-label, single-sequence study. "
3.	Pulmonary Arterial Hypertension 12/01/2021 - "The objective of this study was to develop a comprehensive population model to describe the pharmacokinetics of macitentan and aprocitentan in healthy adults and adult subjects with pulmonary arterial hypertension. " 12/01/2021 - "A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension."
4.	Essential Hypertension 01/01/2020 - "This study examined the dose-response characteristics of aprocitentan, a dual endothelin A/endothelin B receptor antagonist, in patients with essential hypertension. "
5.	Weight Gain 01/01/2021 - "Increases in body weight were observed with aprocitentan (placebo-corrected mean weight gains [90% confidence interval]) of 0.43 [0.05-0.80], 0.77 [0.03-1.51], and 0.83 [0.33-1.32] kg at 10 mg, 25 mg, and 50 mg, respectively. " 01/01/2021 - "As fluid retention and edema are concerns with ERAs, we investigated whether aprocitentan causes weight gain in healthy subjects on a high sodium diet and explored potential mechanisms if occurring. "

Related Drugs and Biologics

1.	Endothelin Receptor Antagonists
2.	Endothelins (Endothelin)
3.	macitentan
4.	Endothelin B Receptor
5.	Proteins (Proteins, Gene)
6.	Antihypertensive Agents (Antihypertensives)
7.	Rosuvastatin Calcium (Crestor)
8.	Endothelin-1 (Endothelin 1)
9.	Salts
10.	Bosentan (Tracleer)

Related Therapies and Procedures

1.	Therapeutics